Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$85.25 USD
+0.19 (0.22%)
Updated May 3, 2024 04:00 PM ET
After-Market: $85.27 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth A Momentum C VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
EW 85.25 +0.19(0.22%)
Will EW be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for EW based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for EW
Is Edwards Lifesciences (EW) Outperforming Other Medical Stocks This Year?
Down -10.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Edwards Lifesciences (EW)
EW: What are Zacks experts saying now?
Zacks Private Portfolio Services
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investing in Edwards Lifesciences (EW)? Don't Miss Assessing Its International Revenue Trends
Other News for EW
Jim Cramer: These Airline Stocks 'Trade Wildly,' Edwards Lifesciences 'At The Right Level To Buy'
East West Petroleum Nears New Zealand Asset Sale Completion
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), Bristol-Myers Squibb (BMY) and Laboratory (LH)
Hold Rating Justified for Edwards Lifesciences Amid TAVR Segment Uncertainties
Maintaining Buy Rating on Edwards Lifesciences Amid Mixed TAVR Performance and Strong TMTT Growth